JNJ
HealthcareJohnson & Johnson
$241.86-0.18 (-0.07%)
Prev Close
$242.04
Open
$244.21
High
$245.59
Low
$241.85
Volume
4.15M
Market Cap
$583.29B
P/E
21.91
Div Yield
0.02%
Over the past 12 months, insider activity at Johnson & Johnson (JNJ) has been dominated by selling, with 1 insider purchase totaling $257.7K and 30 insider sales totaling $224.36M. The most recent insider transaction was by Decker Robert J (officer: VP Corporate Controller), who sold $1.01M worth of shares on Mar 3, 2026. Johnson & Johnson operates in the Healthcare sector, within the Drug Manufacturers - General industry, with a market cap of $583.29B.
Buys (12M)
1
$257.7K
Sells (12M)
30
$224.36M
Net Activity
Net Seller
$224.10M
Active Insiders
13
last 12 mo
JNJ Price Chart
JNJ Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026↗ | Decker Robert J | officer: VP Corporate Controller | Sell | 4,075 | $247.87 | $1.01M | 23,682 |
| Feb 23, 2026↗ | Schmid Timothy | officer: EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 25,447 |
| Feb 20, 2026↗ | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 0 |
| Feb 18, 2026↗ | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | Sell | 6,197 | $243.39 | $1.51M | 23,003 |
| Feb 18, 2026↗ | REED JOHN C | officer: EVP, Innovative Medicine, R&D | Sell | 32,210 | $243.00 | $7.83M | 12,941 |
| Feb 18, 2026↗ | Schmid Timothy | officer: EVP, WW Chair, MedTech | Sell | 22,623 | $244.33 | $5.53M | 26,769 |
| Feb 18, 2026↗ | Swanson James D. | officer: EVP, CIO | Sell | 62,080 | $243.39 | $15.11M | 25,698.1 |
| Feb 18, 2026↗ | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 7,266 | $244.45 | $1.78M | 0 |
| Feb 18, 2026↗ | Wolk Joseph J | officer: Exec VP, CFO | Sell | 89,654 | $242.80 | $21.77M | 38,961 |
| Feb 15, 2026↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 54,844 | $243.01 | $13.33M | 0 |
| Feb 13, 2026↗ | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 10,611 | $243.82 | $2.59M | 0 |
| Feb 13, 2026↗ | Decker Robert J | VP Corporate Controller | Sell | 1,055 | $244.35 | $257.8K | 0 |
| Feb 13, 2026↗ | Duato Joaquin | CEO and Chairman of the Board | Sell | 36,230 | $244.44 | $8.86M | 0 |
| Feb 13, 2026↗ | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 8,361 | $244.41 | $2.04M | 0 |
| Feb 13, 2026↗ | Mulholland Kristen | EVP, Chief HR Officer | Sell | 1,585 | $244.26 | $387.1K | 0 |
| Feb 13, 2026↗ | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 24,910 | $244.33 | $6.09M | 0 |
| Feb 13, 2026↗ | Swanson James D. | EVP, CIO | Sell | 66,293 | $243.46 | $16.14M | 0 |
| Feb 13, 2026↗ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 15,717 | $244.43 | $3.84M | 0 |
| Feb 13, 2026↗ | Wolk Joseph J | Exec VP, CFO | Sell | 107,784 | $243.08 | $26.20M | 0 |
| Jan 28, 2026↗ | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 200,000 | $221.23 | $44.25M | 79,634 |
| Dec 1, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 6,337 | $10.03 | $63.6K | 0 |
| Dec 1, 2025↗ | MORIKIS JOHN G | Director | Buy | 1,250 | $206.15 | $257.7K | 0 |
| Nov 25, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 2,700 | $10.05 | $27.1K | 0 |
| Nov 14, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 1,000 | $10.00 | $10.0K | 0 |
| Nov 10, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 52,532 | $10.21 | $536.3K | 0 |
| Oct 20, 2025↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.19M | 0 |
| Sep 5, 2025↗ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 56,471 | $177.81 | $10.04M | 0 |
| Sep 3, 2025↗ | Forminard Elizabeth | Executive VP, General Counsel | Sell | 9,570 | $177.20 | $1.70M | 0 |
| Aug 25, 2025↗ | Duato Joaquin | CEO and Chairman of the Board | Sell | 125,824 | $179.21 | $22.55M | 0 |
| Aug 18, 2025↗ | Wolk Joseph J | Exec VP, CFO | Sell | 16,820 | $176.91 | $2.98M | 0 |
| Jul 18, 2025↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3.13M | 0 |
| Feb 26, 2025↗ | Decker Robert J | VP Corporate Controller | Sell | 6,999 | $165.88 | $1.16M | 0 |
| Feb 18, 2025↗ | Decker Robert J | VP Corporate Controller | Sell | 824 | $156.46 | $128.9K | 0 |
| Feb 18, 2025↗ | Forminard Elizabeth | Executive VP, General Counsel | Sell | 1,253 | $156.32 | $195.9K | 0 |
| Feb 18, 2025↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 385 | $156.15 | $60.1K | 0 |
| Feb 18, 2025↗ | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 2,250 | $156.49 | $352.1K | 0 |
| Feb 18, 2025↗ | Swanson James D. | EVP, CIO | Sell | 1,740 | $156.54 | $272.4K | 0 |
| Feb 18, 2025↗ | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 3,296 | $156.58 | $516.1K | 0 |
| Feb 18, 2025↗ | Wolk Joseph J | Exec VP, CFO | Sell | 9,080 | $156.58 | $1.42M | 0 |
| Feb 11, 2025↗ | Duato Joaquin | CEO and Chairman of the Board | Sell | 100,643 | $153.12 | $15.41M | 0 |
| Feb 11, 2025↗ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 47,436 | $153.12 | $7.26M | 0 |
| Feb 11, 2025↗ | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 26,076 | $153.12 | $3.99M | 0 |
JNJ Insider Buying Activity
The following table shows recent insider purchases of Johnson & Johnson (JNJ) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025↗ | MORIKIS JOHN G | Director | Buy | 1,250 | $206.15 | $257.7K | 0 |
JNJ Insider Selling Activity
The following table shows recent insider sales of Johnson & Johnson (JNJ) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026↗ | Decker Robert J | officer: VP Corporate Controller | Sell | 4,075 | $247.87 | $1.01M | 23,682 |
| Feb 23, 2026↗ | Schmid Timothy | officer: EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 25,447 |
| Feb 20, 2026↗ | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 0 |
| Feb 18, 2026↗ | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | Sell | 6,197 | $243.39 | $1.51M | 23,003 |
| Feb 18, 2026↗ | REED JOHN C | officer: EVP, Innovative Medicine, R&D | Sell | 32,210 | $243.00 | $7.83M | 12,941 |
| Feb 18, 2026↗ | Schmid Timothy | officer: EVP, WW Chair, MedTech | Sell | 22,623 | $244.33 | $5.53M | 26,769 |
| Feb 18, 2026↗ | Swanson James D. | officer: EVP, CIO | Sell | 62,080 | $243.39 | $15.11M | 25,698.1 |
| Feb 18, 2026↗ | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 7,266 | $244.45 | $1.78M | 0 |
| Feb 18, 2026↗ | Wolk Joseph J | officer: Exec VP, CFO | Sell | 89,654 | $242.80 | $21.77M | 38,961 |
| Feb 15, 2026↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 54,844 | $243.01 | $13.33M | 0 |
| Feb 13, 2026↗ | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 10,611 | $243.82 | $2.59M | 0 |
| Feb 13, 2026↗ | Decker Robert J | VP Corporate Controller | Sell | 1,055 | $244.35 | $257.8K | 0 |
| Feb 13, 2026↗ | Duato Joaquin | CEO and Chairman of the Board | Sell | 36,230 | $244.44 | $8.86M | 0 |
| Feb 13, 2026↗ | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 8,361 | $244.41 | $2.04M | 0 |
| Feb 13, 2026↗ | Mulholland Kristen | EVP, Chief HR Officer | Sell | 1,585 | $244.26 | $387.1K | 0 |
| Feb 13, 2026↗ | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 24,910 | $244.33 | $6.09M | 0 |
| Feb 13, 2026↗ | Swanson James D. | EVP, CIO | Sell | 66,293 | $243.46 | $16.14M | 0 |
| Feb 13, 2026↗ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 15,717 | $244.43 | $3.84M | 0 |
| Feb 13, 2026↗ | Wolk Joseph J | Exec VP, CFO | Sell | 107,784 | $243.08 | $26.20M | 0 |
| Jan 28, 2026↗ | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 200,000 | $221.23 | $44.25M | 79,634 |
| Dec 1, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 6,337 | $10.03 | $63.6K | 0 |
| Nov 25, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 2,700 | $10.05 | $27.1K | 0 |
| Nov 14, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 1,000 | $10.00 | $10.0K | 0 |
| Nov 10, 2025↗ | JOHNSON & JOHNSON | 10% Owner | Sell | 52,532 | $10.21 | $536.3K | 0 |
| Oct 20, 2025↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.19M | 0 |
| Sep 5, 2025↗ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 56,471 | $177.81 | $10.04M | 0 |
| Sep 3, 2025↗ | Forminard Elizabeth | Executive VP, General Counsel | Sell | 9,570 | $177.20 | $1.70M | 0 |
| Aug 25, 2025↗ | Duato Joaquin | CEO and Chairman of the Board | Sell | 125,824 | $179.21 | $22.55M | 0 |
| Aug 18, 2025↗ | Wolk Joseph J | Exec VP, CFO | Sell | 16,820 | $176.91 | $2.98M | 0 |
| Jul 18, 2025↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3.13M | 0 |
| Feb 26, 2025↗ | Decker Robert J | VP Corporate Controller | Sell | 6,999 | $165.88 | $1.16M | 0 |
| Feb 18, 2025↗ | Decker Robert J | VP Corporate Controller | Sell | 824 | $156.46 | $128.9K | 0 |
| Feb 18, 2025↗ | Forminard Elizabeth | Executive VP, General Counsel | Sell | 1,253 | $156.32 | $195.9K | 0 |
| Feb 18, 2025↗ | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 385 | $156.15 | $60.1K | 0 |
| Feb 18, 2025↗ | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 2,250 | $156.49 | $352.1K | 0 |
| Feb 18, 2025↗ | Swanson James D. | EVP, CIO | Sell | 1,740 | $156.54 | $272.4K | 0 |
| Feb 18, 2025↗ | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 3,296 | $156.58 | $516.1K | 0 |
| Feb 18, 2025↗ | Wolk Joseph J | Exec VP, CFO | Sell | 9,080 | $156.58 | $1.42M | 0 |
| Feb 11, 2025↗ | Duato Joaquin | CEO and Chairman of the Board | Sell | 100,643 | $153.12 | $15.41M | 0 |
| Feb 11, 2025↗ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 47,436 | $153.12 | $7.26M | 0 |
| Feb 11, 2025↗ | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 26,076 | $153.12 | $3.99M | 0 |
JNJ Insiders
Similar Stocks to JNJ
LLY
Eli Lilly and Company
$984.11+0.70%
$921.90B
ABBV
AbbVie Inc.
$220.81-2.02%
$398.49B
MRK
Merck & Co., Inc.
$115.92+0.00%
$286.57B
AMGN
Amgen Inc.
$366.74-0.29%
$198.26B
GILD
Gilead Sciences, Inc.
$144.25-0.66%
$180.27B
PFE
Pfizer Inc.
$26.62-0.89%
$152.73B
BMY
Bristol-Myers Squibb Company
$58.93-0.04%
$120.05B
BIIB
Biogen Inc.
$183.58-0.71%
$27.14B